Literature DB >> 7840618

Functional organization of mammalian hexokinases: characterization of chimeric hexokinases constructed from the N- and C-terminal domains of the rat type I and type II isozymes.

H J Tsai1, J E Wilson.   

Abstract

Chimeric hexokinases consisting of either the N-terminal half of Type I hexokinase fused with the C-terminal half of the Type II isozyme (NICII) or the inverse pair (NIICI), along with the parental isozymes, were expressed in COS-1 cells. The thermal stability of the chimeras was intermediate between that of the highly labile Type II isozyme and the relatively stable Type I hexokinase. In their Kms for substrates, Glc and ATP, the chimeric enzymes were similar to the parental isozyme from which the C-terminal half was derived. Although the Type I and Type II isozymes were similar in their sensitivity to inhibition (competitive vs ATP) by the Glc-6-P analogs, 1,5-anhydroglucitol 6-phosphate (AnGlc-6-P), and Glc-1,6-bisphosphate, the chimeric enzymes differed markedly, with the NIICI chimera being much more sensitive and the NICII chimera much less sensitive than either parental form to these inhibitors. In contrast, the response of the chimeras to Pi, either as an antagonist of inhibition by AnGlc-6-P or, at higher concentrations, as an inhibitor, was correlated with the origin of the N-terminal domain. The results are consistent with the view that catalytic function is associated with the C-terminal domain of the Type I isozyme, with regulatory function--inhibition by Glc-6-P and its analogs and antagonism of this inhibition by Pi--being mediated by the N-terminal domain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840618     DOI: 10.1006/abbi.1995.1029

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

Review 1.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

2.  Cleavage of disulfide bonds in mouse spermatogenic cell-specific type 1 hexokinase isozyme is associated with increased hexokinase activity and initiation of sperm motility.

Authors:  Noriko Nakamura; Antonio Miranda-Vizuete; Kiyoshi Miki; Chisato Mori; Edward M Eddy
Journal:  Biol Reprod       Date:  2008-05-28       Impact factor: 4.285

3.  Binding of rat brain hexokinase to recombinant yeast mitochondria: effect of environmental factors and the source of porin.

Authors:  C Aflalo; H Azoulay
Journal:  J Bioenerg Biomembr       Date:  1998-06       Impact factor: 2.945

Review 4.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Bovine hexokinase type I: full-length cDNA sequence and characterisation of the recombinant enzyme.

Authors:  Francesca Andreoni; Giordano Serafini; Maria Elena Laguardia; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 6.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Biochim Biophys Acta       Date:  2010-04-08

7.  Hexokinase 'binding sites' of normal and tumoral human brain mitochondria.

Authors:  A Golestani; M Nemat-Gorgani
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

8.  In-silico and in-vitro investigation on the phenylalanine metabolites' interactions with hexokinase of Rat's brain mitochondria.

Authors:  Nasrin Ziamajidi; Shirin Jamshidi; Abdolvahab Ehsani-Zonouz
Journal:  J Bioenerg Biomembr       Date:  2017-03-08       Impact factor: 2.945

9.  Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme.

Authors:  Jeremy W Chambers; Margaret T Kearns; Meredith T Morris; James C Morris
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.